Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: oversold as market dips and picks-up at the close leaving the sector sucking pond water

December 19, 2018 3:49am

“Bottom” development has to be close; some internal breadth have matched their lows from October

Pre-open indications: 5 HIT and 2 MISS

Out and about: AxoGen (AXGN -$6.17 or -22.41 to $21.36) sank in response to a negative report from an investor that stands to gain a great deal if the stock tanks. The short-seller has convinced enough investors AXGN's in trouble to drive the stock 22.4% lower on Tuesday. Real or imagined, wouldn't have such a big effect on the stock if investors weren't still waiting for crucial clinical trial results. AXGN began distributing the Avance Nerve Graft in 2007, but it isn't approved by the FDA yet. To satisfy the regulator, AXGN started a registry study to compare outcomes between patients receiving standard care and AxoGen's cadaver-derived product.

Investors should be reading about today’s final “figures” – be a subscriber and be ready for tomorrow’s session! As I have stated … today’s tin could be tomorrow’s gold!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

39 min ago
RegMed Investors (RMi) Closing Bell: hammered

9 hours 30 min ago
RegMed Investors’ (RMi) pre-open: expectation versus reality

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.